Pulmonary Manifestations and Progression of Lung Disease in Juvenile-onset Mixed Connective Tissue Disease

REFERENCES

1. 1.↵
   1. Kasukawa R,
   2. Sharp GC

   1. Kasukawa R,
   2. Tojo T,
   3. Miyawaki S

   . Preliminary diagnostic criteria for classification of mixed connective tissue disease. In: Kasukawa R, Sharp GC, editors. Mixed connective tissue disease and antinuclear antibodies Amsterdam: Elsevier; 1987:41–7.
2. 2.↵
   1. Gunnarsson R,
   2. Aalokken TM,
   3. Molberg O,
   4. Lund MB,
   5. Mynarek GK,
   6. Lexberg AS,
   7. et al.

   Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study. Ann Rheum Dis 2012;71:1966–72.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Reiseter S,
   2. Gunnarsson R,
   3. Mogens Aalokken T,
   4. Brit Lund M,
   5. Mynarek G,
   6. Corander J,
   7. et al.

   Progression and mortality of interstitial lung disease in mixed connective tissue disease: a long-term observational nationwide cohort study. Rheumatology 2018;57:255–62.

   OpenUrl
4. 4.↵
   1. Hajas A,
   2. Szodoray P,
   3. Nakken B,
   4. Gaal J,
   5. Zold E,
   6. Laczik R,
   7. et al.

   Clinical course, prognosis, and causes of death in mixed connective tissue disease. J Rheumatol 2013;40:1134–42.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Fagundes MN,
   2. Caleiro MT,
   3. Navarro-Rodriguez T,
   4. Baldi BG,
   5. Kavakama J,
   6. Salge JM,
   7. et al.

   Esophageal involvement and interstitial lung disease in mixed connective tissue disease. Respir Med 2009;103:854–60.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Kawano-Dourado L,
   2. Baldi BG,
   3. Kay FU,
   4. Dias OM,
   5. Gripp TE,
   6. Gomes PS,
   7. et al.

   Pulmonary involvement in long-term mixed connective tissue disease: functional trends and image findings after 10 years. Clin Exp Rheumatol 2015;33:234–40.

   OpenUrl
7. 7.↵
   1. Bodolay E,
   2. Szekanecz Z,
   3. Devenyi K,
   4. Galuska L,
   5. Csipo I,
   6. Vegh J,
   7. et al.

   Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology 2005;44:656–61.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Sharp GC,
   2. Irvin WS,
   3. Tan EM,
   4. Gould RG,
   5. Holman HR

   . Mixed connective tissue disease—an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972;52:148–59.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Lundberg IE

   . The prognosis of mixed connective tissue disease. Rheum Dis Clin North Am 2005;31:535–47.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Kotajima L,
    2. Aotsuka S,
    3. Sumiya M,
    4. Yokohari R,
    5. Tojo T,
    6. Kasukawa R

    . Clinical features of patients with juvenile onset mixed connective tissue disease: analysis of data collected in a nationwide collaborative study in Japan. J Rheumatol 1996;23:1088–94.

    OpenUrlPubMed
11. 11.↵
    1. Burdt MA,
    2. Hoffman RW,
    3. Deutscher SL,
    4. Wang GS,
    5. Johnson JC,
    6. Sharp GC

    . Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 1999;42:899–909.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Aalokken TM,
    2. Lilleby V,
    3. Soyseth V,
    4. Mynarek G,
    5. Pripp AH,
    6. Johansen B,
    7. et al.

    Chest abnormalities in juvenile-onset mixed connective tissue disease: assessment with high-resolution computed tomography and pulmonary function tests. Acta Radiol 2009;50:430–6.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Mier RJ,
    2. Shishov M,
    3. Higgins GC,
    4. Rennebohm RM,
    5. Wortmann DW,
    6. Jerath R,
    7. et al.

    Pediatric-onset mixed connective tissue disease. Rheum Dis Clin North Am 2005;31:483–96.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Tellier S,
    2. Bader-Meunier B,
    3. Quartier P,
    4. Belot A,
    5. Deslandre C,
    6. Kone-Paut I,
    7. et al.

    Initial presentation and outcome of pediatric-onset mixed connective tissue disease: A French multicenter retrospective study. Joint Bone Spine 2016;83:369–71.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Yokota S

    . Mixed connective tissue disease in childhood. Acta Paediatr Jpn 1993;35:472–9.

    OpenUrlPubMed
16. 16.↵
    1. Kasukawa R,
    2. Sharp GC

    1. Alarcón-Segovia D,
    2. Villareal M

    . Classification and diagnostic criteria for mixed connective tissue disease. In: Kasukawa R, Sharp GC, editors. Mixed connective tissue disease and antinuclear antibodies. Amsterdam: Elsevier; 1987:33–40.
17. 17.↵
    1. Hetlevik SO,
    2. Flato B,
    3. Rygg M,
    4. Nordal EB,
    5. Brunborg C,
    6. Hetland H,
    7. et al.

    Long-term outcome in juvenile-onset mixed connective tissue disease: a nationwide Norwegian study. Ann Rheum Dis 2017;76:159–65.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Hansell DM,
    2. Bankier AA,
    3. MacMahon H,
    4. McLoud TC,
    5. Muller NL,
    6. Remy J

    . Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008;246:697–722.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Miller MR,
    2. Hankinson J,
    3. Brusasco V,
    4. Burgos F,
    5. Casaburi R,
    6. Coates A,
    7. et al;
    8. ATS/ERS Task Force

    . Standardisation of spirometry. Eur Respir J 2005;26:319–38.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Macintyre N,
    2. Crapo RO,
    3. Viegi G,
    4. Johnson DC,
    5. van der Grinten CP,
    6. Brusasco V,
    7. et al.

    Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005;26:720–35.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Pellegrino R,
    2. Viegi G,
    3. Brusasco V,
    4. Crapo RO,
    5. Burgos F,
    6. Casaburi R,
    7. et al.

    Interpretative strategies for lung function tests. Eur Respir J 2005;26:948–68.

    OpenUrlFREE Full Text
22. 22.↵
    1. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories

    . ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111–7.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Borg G

    . Psychophysical scaling with applications in physical work and the perception of exertion. Scand J Work Environ Health 1990;16 Suppl 1:55–8.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Foeldvari I,
    2. Nihtyanova SI,
    3. Wierk A,
    4. Denton CP

    . Characteristics of patients with juvenile onset systemic sclerosis in an adult single-center cohort. J Rheumatol 2010;37:2422–6.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Sanner H,
    2. Aalokken TM,
    3. Gran JT,
    4. Sjaastad I,
    5. Johansen B,
    6. Flato B

    . Pulmonary outcome in juvenile dermatomyositis: a case-control study. Ann Rheum Dis 2011;70:86–91.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    1. Lilleby V,
    2. Aalokken TM,
    3. Johansen B,
    4. Forre O

    . Pulmonary involvement in patients with childhood-onset systemic lupus erythematosus. Clin Exp Rheumatol 2006;24:203–8.

    OpenUrlPubMed
27. 27.↵
    1. Chetta A,
    2. Zanini A,
    3. Pisi G,
    4. Aiello M,
    5. Tzani P,
    6. Neri M,
    7. et al.

    Reference values for the 6-min walk test in healthy subjects 20–50 years old. Respir Med 2006;100:1573–8.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Steen VD,
    2. Graham G,
    3. Conte C,
    4. Owens G,
    5. Medsger TA Jr

    . Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992;35:765–70.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Sandler M

    . Is the lung a ‘target organ’ in diabetes mellitus? Arch Intern Med 1990;150:1385–8.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Goh NS,
    2. Hoyles RK,
    3. Denton CP,
    4. Hansell DM,
    5. Renzoni EA,
    6. Maher TM,
    7. et al.

    Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol 2017;69:1670–8.

    OpenUrl
31. 31.↵
    1. Le Gouellec N,
    2. Duhamel A,
    3. Perez T,
    4. Hachulla AL,
    5. Sobanski V,
    6. Faivre JB,
    7. et al.

    Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease. PLoS One 2017;12:e0181692.

    OpenUrl
32. 32.↵
    1. Molberg O,
    2. Hoffmann-Vold AM

    . Interstitial lung disease in systemic sclerosis: progress in screening and early diagnosis. Curr Opin Rheumatol 2016;28:613–8.

    OpenUrl
33. 33.↵
    1. Hoffmann-Vold AM,
    2. Aalokken TM,
    3. Lund MB,
    4. Garen T,
    5. Midtvedt O,
    6. Brunborg C,
    7. et al.

    Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis. Arthritis Rheumatol 2015;67:2205–12.

    OpenUrl